Celgene Corporation (CELG)’s Pancreatic Cancer Base Hit
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 24, 2013 - 1:05pm
Celgene Corporation (NASDAQ:CELG) got a solid base hit but no home run. The company announced Tuesday evening that its phase 3 study of Abraxane in combination with gemcitabine for treating metastatic pancreatic cancer showed significant improvement in overall survival. However, shares were down slightly in after-hours trading. Here’s why. What it means Relatively speaking, Abraxane [...]
Continue reading this article »Share This Article: